<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940114-2-00066</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The public workshop will be held on January 31, 1994, 8:30 a.m. to 5 p.m. Registration will be between 8 a.m. and 8:30 a.m. Interested persons are encouraged to preregister before January 21, 1994, by telephoning the contact person. Space for the workshop is limited. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0490]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <DOCTITLE>Improvements in the Drug Master File System; Notice of a Public Workshop</DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is announcing a public workshop on possible improvements in the drug master file (DMF) system. The purpose of this workshop is to exchange ideas with interested persons about ways of improving the drug substance and drug substance intermediate Type II DMF review process. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The public workshop will be held on January 31, 1994, 8:30 a.m. to 5 p.m. Registration will be between 8 a.m. and 8:30 a.m. Interested persons are encouraged to preregister before January 21, 1994, by telephoning the contact person. Space for the workshop is limited. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The public workshop will be held at the Parklawn Bldg., conference rms. D and E, 5600 Fishers Lane, Rockville, MD 20857.  <!-- PJG 0012 frnewline --> Written comments regarding the workshop may be submitted to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. Copies of a report entitled ``Recommendations for Improvement in FDA's Drug Master File System'' may be obtained from the Freedom of Information Office (HFI&hyph;35), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Eric P. Duffy, Center for Drug Evaluation and Research (HFD&hyph;635), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;0360. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  A DMF is a submission to FDA that may be used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs (see 21 CFR 314.420). The submission of a DMF is not required by law or FDA regulation. A DMF is submitted solely at the discretion of the holder. The information contained in the DMF may be used to support an investigational new drug application, a new drug application, an abbreviated new drug application, another DMF, an export application, or amendments and supplements to any of these. FDA's Center for Drug Evaluation and Research (CDER) reviews the DMF only when it is referenced in such submissions.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Five types of DMF's exist regarding the following topics: Type I_ manufacturing site, facilities, operating procedures, and personnel; Type II_drug substance, drug substance intermediate, and material used in their preparation, or drug product; Type III_packaging material; Type IV_excipient, colorant, flavor, essence, or material used in their preparation; and Type V_FDA-accepted reference information.  <!-- PJG 0012 frnewline --> CDER is considering ways to improve the DMF system, especially Type II DMF's, which often constitute a critical part of a submission. The workshop will focus on alternative ways for CDER to review Type II DMF's for drug substances and intermediates. CDER's Chemistry, Manufacturing and Controls Coordinating Committee has recommended changes to the DMF review process in a report entitled ``Recommendations for Improvement in FDA's Drug Master File System,'' dated November 2, 1993. The report is available from the Freedom of Information Office (address above) or may be viewed at the Dockets Management Branch (address above) [Docket No. 90S&hyph;0308 (document #M&hyph;203)]. <!-- PJG 0012 frnewline --> A tentative agenda for the public workshop is as follows: <!-- PJG 0012 frnewline -->  Morning session, 8:30 a.m. to 12:30 p.m. <!-- PJG 0012 frnewline --> 1. FDA presentations: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Recommended review processes for Type II DMF's (drug substances and intermediates) <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> a. existing DMF system;  <!-- PJG 0012 frnewline --> b. suggested improvements to the existing DMF system;  <!-- PJG 0012 frnewline --> c. abbreviated antibiotic application model_approval; and <!-- PJG 0012 frnewline --> d. Type II DMF ``authorization.''  <!-- PJG 0012 frnewline --> 2. Presentations by industry representatives: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Perspectives on the Type II DMF review process and proposals. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3. Presentations by other interested persons/Questions for presenters/ Open discussion  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Approvals/nonapprovals/other_pros/cons. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Afternoon session, 1:30 p.m. to 5 p.m.  <!-- PJG 0012 frnewline --> 1. Overview_Other DMF systems for drug substances and intermediates_foreign models. <!-- PJG 0012 frnewline --> a. European Community Drug Substance DMF Format and Content; and <!-- PJG 0012 frnewline --> b. Canadian Drug Substance DMF Format and Content. <!-- PJG 0012 frnewline --> 2. Presentations by other interested persons/Questions for presenters/Open discussion. <!-- PJG 0012 frnewline --> A transcript and summary of the workshop will be available from the Freedom of Information Office (address above) approximately 10 days after the workshop at a cost of 10 cents per page. <!-- PJG 0012 frnewline --> Interested persons may submit comments on the workshop to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG 007 0141 unknown --> 001To permit time for all interested persons to submit data, information, or views on this subject, the docket for the workshop will remain open until March 14, 1994. Persons who wish to provide additional materials for consideration should file these materials with the Dockets Management Branch (address above).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: January 10, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Michael R. Taylor, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;1048 Filed 1&hyph;12&hyph;94; 11:29 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            